证券代码：688177 证券简称：百奥泰 公告编号：2025-037 百奥泰生物制药股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 4 月 30 日 （二） 股东大会召开的地点：广州市黄埔区永和经济开发区摇田河大街 155 号 E 栋 5K702 会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 86 | | --- | --- | | 普通股股东人数 | 86 | | 2、出席会议的股东所持有的表决权数量 | 313,141,286 | | 普通股股东所持有表决权数量 | 313,141,286 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 75.6234 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 75 ...

证券代码： 688177 证券简称： 百奥泰 公告编号：2025-038 百奥泰生物制药股份有限公司 关于完成董事会换届选举及聘任高级管理人员 和证券事务代表、内部审计负责人的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 百奥泰生物制药股份有限公司（以下简称"百奥泰"或"公司"）于 2025 年 4 月 30 日召开了 2024 年年度股东大会，选举产生了公司第三届董事会非独立董事 五名、独立董事三名，与公司于 2025 年 4 月 10 日召开的职工代表大会选举产生 的职工代表董事共同组成了公司第三届董事会，任期自股东大会审议通过之日起 三年。 经全体董事一致同意，豁免董事会的提前通知程序和期限，公司于同日召开 第三届董事会第一次会议，选举产生了董事长、董事会各专门委员会委员及主任 委员，并聘任高级管理人员、证券事务代表及内部审计负责人。现就相关情况公 告如下： 一、 公司换届选举情况 （一）董事选举情况 公司于 2025 年 4 月 30 日召开了 2024 年年度股东大会，本次会议采用累积 投票制的方式选举 ...

Investment Rating - The report does not explicitly provide an investment rating for the industry. Core Insights - The report emphasizes the importance of understanding the funding side of the U.S. innovative drug market, particularly how capital flows influence the industry dynamics [4][7]. - It highlights that large multinational corporations (MNCs) dominate the market due to their substantial cash reserves, enabling them to make significant upfront payments for innovative drug licenses [9][13]. - The report discusses the reliance of biotech companies on capital market financing, indicating that these firms often lack sufficient cash reserves to support their operations independently [18][30]. Summary by Sections Section 1: Where Does the Money for Innovative Drug Licensing Come From? - The report explores the sources of funding for innovative drug licensing, focusing on the role of MNCs and their financial capabilities [7][9]. Section 2: Financing Dependency - Biotech companies are heavily reliant on financing, with their cash flow primarily supported by capital market activities rather than product sales [18][30]. Section 3: U.S. Fiscal Support and Ecological Monopoly - The report discusses how the U.S. government and fiscal policies create an ecosystem that supports the dominance of MNCs in the innovative drug market [7][30]. Section 4: Liquidity Clock - The concept of a "liquidity clock" is introduced, illustrating how the interplay between funding and assets shapes the investment landscape in the U.S. innovative drug sector [4][7].

Financial Data and Indicators - The basic earnings per share for Q1 2025 is -0.2300 yuan, showing a 20.69% improvement compared to -0.2900 yuan in Q1 2024 [1] - The net asset per share decreased by 43.94% to 1.48 yuan from 2.64 yuan in the previous year [1] - The operating revenue for Q1 2025 increased by 27.78% to 2.07 billion yuan compared to 1.62 billion yuan in Q1 2024 [1] - The net profit for Q1 2025 is -0.93 billion yuan, an improvement of 21.85% from -1.19 billion yuan in Q1 2024 [1] - The return on equity for Q1 2025 is -14.11%, a decline of 36.72% from -10.32% in Q1 2024 [1] Shareholder Information - The top ten unrestricted shareholders hold a total of 31,408.05 million shares, accounting for 75.84% of the circulating shares, with a decrease of 384.87 million shares compared to the previous period [2] - Guangzhou Qixi Group Co., Ltd. holds 15,999.03 million shares, representing 38.64% of the total share capital, with no change [3] - Therabio International Limited holds 4,717.77 million shares, accounting for 11.39% of the total share capital, with no change [3] - New Yu City Qiheng Management Consulting Partnership (Limited Partnership) decreased its holdings by 384.87 million shares to 1,614.31 million shares, representing 3.90% of the total share capital [3] Dividend Distribution - The company will not distribute dividends or transfer shares this time [4]

证券代码：688177 证券简称：百奥泰 公告编号：2025-036 百奥泰生物制药股份有限公司 第二届监事会第二十次会议决议的公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、 监事会会议召开情况 百奥泰生物制药股份有限公司（以下简称"公司"）第二届监事会第二十次会 议（以下简称"本次会议"）于 2025 年 4 月 28 日在线上以通讯方式召开，本次会 议通知及相关材料已于 2025 年 4 月 17 日以书面方式送达公司全体监事。本次会 议由监事会主席吴晓云召集并主持，会议应出席监事 3 人，实际出席监事 3 人。 会议的召集、召开和表决程序符合《中华人民共和国公司法》《上海证券交易所 科创板股票上市规则》等相关法律、行政法规、规范性文件及《百奥泰生物制药 股份有限公司章程》（以下简称"《公司章程》"）的有关规定。 二、 监事会会议审议情况 经与会监事充分讨论，本次会议以记名投票方式审议通过了如下议案： 审议通过《关于公司 2025 年第一季度报告的议案》 经审议，监事会认为公司 2025 年第一季度报告的 ...

Financial Performance - The company's revenue for Q1 2025 was CNY 206,555,604.43, representing a 27.83% increase compared to CNY 161,591,937.51 in the same period last year[3] - The net profit attributable to shareholders was a loss of CNY 93,330,977.90, an improvement from a loss of CNY 118,958,055.48 year-over-year[3] - The net loss for Q1 2025 was ¥93,330,977.90, an improvement from a net loss of ¥118,958,055.48 in Q1 2024[20] - The company reported a total comprehensive loss of -93,667,998.14 RMB for Q1 2025, compared to -119,035,070.61 RMB in Q1 2024, showing a reduction in losses[35] Cash Flow and Liquidity - The net cash flow from operating activities was CNY 79,416,905.66, a significant recovery from a negative cash flow of CNY 64,803,155.03 in the previous year[3] - Operating cash flow for Q1 2025 was ¥79,416,905.66, a significant improvement from -¥64,803,155.03 in Q1 2024[25] - Cash inflow from operating activities in Q1 2025 was 389,351,258.04 RMB, compared to 220,047,817.51 RMB in Q1 2024, reflecting a growth of about 77%[37] - The total cash and cash equivalents at the end of Q1 2025 reached 472,171,686.61 RMB, up from 292,801,722.94 RMB at the end of Q1 2024, representing an increase of approximately 61.4%[38] Research and Development - R&D expenses totaled CNY 180,224,489.76, which is a 5.01% increase from CNY 171,622,215.16, accounting for 87.25% of revenue, down from 106.21%[3] - R&D expenses increased to ¥180,224,489.76 in Q1 2025, compared to ¥171,622,215.16 in Q1 2024, marking a growth of 5.8%[19] - The company continues to focus on R&D and market expansion strategies to improve future performance[19] Assets and Liabilities - Total assets increased by 6.35% to CNY 2,345,641,403.78 from CNY 2,205,537,745.47 at the end of the previous year[4] - Total assets increased to ¥2,345,641,403.78 in Q1 2025 from ¥2,205,537,745.47 in Q1 2024, representing a growth of 6.4%[17] - Total liabilities rose to ¥1,730,911,199.49 in Q1 2025, up from ¥1,497,448,743.34 in Q1 2024, indicating an increase of 15.6%[16] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 8,526[9] - Guangzhou Qixi Group Co., Ltd. holds 38.64% of the shares, making it the largest shareholder[10] - Therabio International Limited is the second largest shareholder with 11.39% of the shares[10] Government Support - The company received government subsidies amounting to CNY 6,233,653.05, which positively impacted the financial results[5] Other Financial Metrics - The weighted average return on equity was -14.11%, a decrease of 3.79 percentage points from -10.32% in the previous year[3] - Basic and diluted earnings per share for Q1 2025 were both -¥0.23, compared to -¥0.29 in Q1 2024[21] - The company reported a net profit margin improvement with a net income of ¥6,228,094.38 in Q1 2025, compared to ¥2,518,299.72 in Q1 2024[33]

Investment Rating - The report does not explicitly state an investment rating for the industry, but it suggests a long-term focus on domestic innovative drugs in the oncology field and AI medical investment opportunities [3][4]. Core Insights - The pharmaceutical and biotechnology sector saw a weekly increase of 1.16%, outperforming the Wind All A index (1.15%) and the CSI 300 index (0.38%) [3][8]. - The upcoming ASCO conference is highlighted as a significant event for domestic innovative drug companies, with over 70 oral presentations and more than 10 major studies expected [3][4]. - The Ministry of Industry and Information Technology and six other departments issued a plan for the digital transformation of the pharmaceutical industry, aiming for significant advancements by 2027 and full coverage by 2030 [3][4]. Market Weekly Review - The pharmaceutical and biotechnology sector increased by 1.16% from April 21 to April 25, outperforming the Wind All A index and the CSI 300 index [3][8]. - Notable performers included medical research outsourcing (6.34%) and raw materials (4.72%), while blood products (-3.26%) and vaccines (-6.38%) continued to decline [3][9]. - Individual stock performances showed significant gains for Yong'an Pharmaceutical (31.4%), Shuyou Shen (28.4%), and Erkang Pharmaceutical (27.7%), while *ST Jiyuan (-43.2%), Nanhua Biological (-35.3%), and Shuangcheng Pharmaceutical (-27.7%) faced substantial losses [3][11]. Industry News and Key Company Announcements - On April 25, Kangfang Bio announced FDA approval for its drug Anike for the treatment of recurrent or metastatic nasopharyngeal carcinoma [12]. - The same day, Kangfang Bio also reported the approval of its PD-1/VEGF bispecific antibody for first-line treatment of specific lung cancer types [13]. - The digital transformation plan for the pharmaceutical industry aims to enhance competitiveness and quality management through AI and data integration by 2030 [3][4].

中国经济网北京4月24日讯 百奥泰(688177.SH)昨晚发布股东减持股份计划公告。 截至公告披露日，新余市启恒管理咨询合伙企业(有限合伙)(曾用名："东台市启恒医药合伙企业(有 限合伙)""珠海吉富启恒医药投资合伙企业(有限合伙)"，以下简称"新余启恒")及其一致行动人汇天泽投资 有限公司(以下简称"汇天泽")合计持有百奥泰生物制药股份有限公司(以下简称"公司")20,704,000股，占 公司总股本5.00%，其中流通股股份数量为20,704,000股，占公司总股本5.00%。 | 股东名称 | 新余启恒 | | --- | --- | | 计划减持数量 | 不超过:8,281,600 股 | | 计划减持比例 | 不超过:2.00% | | 减持方式及对应减持数量 | 集中竞价减持,不超过:4,140,800 股 | | | 大宗交易减持,不超过:4,140,800 股 | | 减持期间 | 2025年5月20日~2025年8月19日 | | 拟减持股份来源 | IPO 前取得 | | 拟减持原因 | 项目退出及资金安排 | 百奥泰于2020年2月21日在上交所科创板上市，发行价格为32.76元/股， ...

Group 1 - Shareholders of Tietuo Machinery plan to reduce their holdings by up to 1,800,000 shares, representing 1.95% of the total share capital, within 15 trading days until August 1, 2025 [1] - Senior management of Upower Electric completed their share reduction plan, with one executive reducing 1,605,000 shares, accounting for 0.0448% of the total share capital after excluding repurchased shares [2] - Jiangsu Jianghai Machinery, a major shareholder of Zhonghuan Hailu, has completed its share reduction plan, reducing 975,908 shares, which is 0.9759% of the total share capital [3] Group 2 - Major shareholders of Duopule plan to reduce their holdings by up to 3,000,000 shares, or 4.85% of the total share capital, within three months after 15 trading days [4] - Shareholders of Jinpu Garden plan to reduce their holdings by up to 1,839,313 shares, each accounting for 1% of the total share capital, within three months [5] - Major shareholders of Liaoning Energy plan to reduce their holdings by up to 39,660,520 shares, representing 3% of the total share capital, within three months after 15 trading days [6] Group 3 - Senior management of Qianzhao Optoelectronics has terminated their share reduction plan without executing any share sales [7] - Major shareholders of Wolong Nuclear Materials plan to reduce their holdings by up to 24,926,600 shares, or 2% of the total share capital, within three months after 15 trading days [8] - Major shareholders of Taiyong Changzheng plan to reduce their holdings by up to 6,695,765 shares, representing 3% of the total share capital, within three months after 15 trading days [9] Group 4 - Major shareholders of Dagang Holdings plan to reduce their holdings by up to 9,520,000 shares, approximately 3% of the total share capital, within three months after 15 trading days [10] - Directors of Yawey Holdings plan to reduce their holdings by up to 4,716,250 shares, or 0.86% of the total share capital, within three months after 15 trading days [11] - Shareholders of Source Fly Pet plan to reduce their holdings by up to 5,651,413 shares, representing 3% of the total share capital, within three months after 15 trading days [12] Group 5 - Major shareholders of Jiangsu Boyun plan to reduce their holdings by up to 2,913,999 shares, or 3% of the total share capital, within three months after 15 trading days [13] - Directors of Supor plan to reduce their holdings by a total of 99,080 shares within three months after 15 trading days [14] - Major shareholders of Yinglian Holdings plan to reduce their holdings by up to 10,458,200 shares, each accounting for 2.50% of the total share capital, within three months after 15 trading days [15]